The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

BUTYROPHENONE     1-phenylbutan-1-one

Synonyms: SureCN82532, AGN-PC-0052JW, CHEMBL193524, NSC-8463, ACMC-1AMR6, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of NSC8463

 

Psychiatry related information on NSC8463

 

High impact information on NSC8463

 

Chemical compound and disease context of NSC8463

 

Biological context of NSC8463

 

Anatomical context of NSC8463

 

Associations of NSC8463 with other chemical compounds

 

Gene context of NSC8463

 

Analytical, diagnostic and therapeutic context of NSC8463

References

  1. Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease. DesJarlais, R.L., Seibel, G.L., Kuntz, I.D., Furth, P.S., Alvarez, J.C., Ortiz de Montellano, P.R., DeCamp, D.L., Babé, L.M., Craik, C.S. Proc. Natl. Acad. Sci. U.S.A. (1990) [Pubmed]
  2. Antipsychotics and the risk of sudden cardiac death. Straus, S.M., Bleumink, G.S., Dieleman, J.P., van der Lei, J., 't Jong, G.W., Kingma, J.H., Sturkenboom, M.C., Stricker, B.H. Arch. Intern. Med. (2004) [Pubmed]
  3. Beta-phenylethylamine (PEA): an endogenous anxiogen? Three series of experimental data. Lapin, I.P. Biol. Psychiatry (1990) [Pubmed]
  4. Clozapine treatment after agranulocytosis induced by classic neuroleptics. Bauer, M., Mackert, A. Journal of clinical psychopharmacology. (1994) [Pubmed]
  5. The evolving management of migraine. Ashkenazi, A., Silberstein, S.D. Curr. Opin. Neurol. (2003) [Pubmed]
  6. Carbamazepine in the treatment of neuroleptic malignant syndrome. Thomas, P., Maron, M., Rascle, C., Cottencin, O., Vaiva, G., Goudemand, M. Biol. Psychiatry (1998) [Pubmed]
  7. A study of clinical response to different kinds of neuroleptics in first time medicated schizophrenics. Kadota, K. Jpn. J. Psychiatry Neurol. (1992) [Pubmed]
  8. Bromperidol, a new potent neuroleptic of the butyrophenone series. A comparison of the effects of bromperidol and haloperidol in intracranial self-stimulation. Wauquier, A., Niemegeers, C.J. Arzneimittel-Forschung. (1976) [Pubmed]
  9. Influence of neuroleptics on the metabolism of tricyclic antidepressants--in vitro experiments with rat liver microsomes. Krüger, R., Hölzl, G., Kuss, H.J., Schefold, L. Biol. Psychiatry (1986) [Pubmed]
  10. Heat treatment mimics guanosine-5'-triphosphate effects on dopaminergic 3H-ligand binding to bovine caudate membranes. Hamblin, M.W., Creese, I. Mol. Pharmacol. (1982) [Pubmed]
  11. Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. Diav-Citrin, O., Shechtman, S., Ornoy, S., Arnon, J., Schaefer, C., Garbis, H., Clementi, M., Ornoy, A. The Journal of clinical psychiatry. (2005) [Pubmed]
  12. Antipsychotic and antidepressant drug use in the elderly and the risk of venous thromboembolism. Ray, J.G., Mamdani, M.M., Yeo, E.L. Thromb. Haemost. (2002) [Pubmed]
  13. 2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 1. van Wijngaarden, I., Kruse, C.G., van Hes, R., van der Heyden, J.A., Tulp, M.T. J. Med. Chem. (1987) [Pubmed]
  14. Tardive dyskinesia in schizophrenic outpatients: prevalence and significant variables. Ezrin-Waters, C., Seeman, M.V., Seeman, P. The Journal of clinical psychiatry. (1981) [Pubmed]
  15. Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. Pomeroy, M., Fennelly, J.J., Towers, M. Cancer Chemother. Pharmacol. (1986) [Pubmed]
  16. Investigation of the butyrophenone tranquilizer azaperone and its main metabolites with the Salmonella/microsome test. Scheutwinkel-Reich, M., Preiss, A.M., Fülle, I., Grohmann, H.G., Stan, H.J. Mutat. Res. (1982) [Pubmed]
  17. Mutagenic and leukemogenic activity of haloperidol: a negative study. Van Cauteren, H., Vanparys, P., de Meester, C., Lambotte-Vandepaer, M., Vandenberghe, J., Marsboom, R. Drug and chemical toxicology. (1987) [Pubmed]
  18. Discrimination of multiple [3H]5-hydroxytryptamine binding sites by the neuroleptic spiperone in rat brain. Pedigo, N.W., Yamamura, H.I., Nelson, D.L. J. Neurochem. (1981) [Pubmed]
  19. Electrophysiological effects of melperone in the dog heart in situ - a new antiarrhythmic drug. Refsum, H., Amlie, J.P., Platou, E.S., Owren, T., Landmark, K. Cardiovasc. Res. (1981) [Pubmed]
  20. Increased serum prolactin levels during phenothiazine and butyrophenone treatment of six postpartum women. Goode, D.J., Meltzer, H.Y., Fang, V.S. Psychoneuroendocrinology (1980) [Pubmed]
  21. Screening procedure for detecting butyrophenone and bisfluorophenyl neuroleptics in urine using a computerized gas chromatographic-mass spectrometric technique. Maurer, H., Pfleger, K. J. Chromatogr. (1983) [Pubmed]
  22. Potentiation by spiperone and other butyrophenones of fluid secretion by isolated salivary glands of ixodid ticks. Wong, D.L., Kaufman, W.R. Eur. J. Pharmacol. (1981) [Pubmed]
  23. Production of catalepsy and depletion of brain monoamines by a butyrophenone derivative. Fuenmayor, L.D., Vogt, M. Br. J. Pharmacol. (1979) [Pubmed]
  24. Evidence for dopaminergic binding sites in the human adrenal cortex. Stern, N., Ozaki, L., Tuck, M.L. Metab. Clin. Exp. (1986) [Pubmed]
  25. The effect of neuroleptic derivatives of butyrophenone on the uptake of 5-HT by human blood platelets. Oxenkrug, G.F. J. Pharm. Pharmacol. (1978) [Pubmed]
  26. The acute effects of central- and peripheral-acting dopamine antagonists on plasma HVA in schizophrenic patients. Konicki, P.E., Owen, R.R., Litman, R.E., Pickar, D. Life Sci. (1991) [Pubmed]
  27. Aging and haloperidol-induced dopamine turnover in the nigro-striatal pathway of C57BL/6J mice. Severson, J.A., Osterburg, H.H., Finch, C.E. Neurobiol. Aging (1981) [Pubmed]
  28. Improved delineation of human dopamine receptors using [18F]-N-methylspiroperidol and PET. Arnett, C.D., Wolf, A.P., Shiue, C.Y., Fowler, J.S., MacGregor, R.R., Christman, D.R., Smith, M.R. J. Nucl. Med. (1986) [Pubmed]
  29. Syntheses and specific activity determinations of no-carrier-added (NCA) F-18-labeled butyrophenone neuroleptics--benperidol, haloperidol, spiroperidol, and pipamperone. Shiue, C.Y., Fowler, J.S., Wolf, A.P., Watanabe, M., Arnett, C.D. J. Nucl. Med. (1985) [Pubmed]
  30. Dynamic cation-exchange systems for the separation of drugs derived from butyrophenone and diphenylpiperidine by high-performance liquid chromatography and applied in the determination of halopemide in plasma. van Rooij, H.H., Waterman, R.L., Kraak, J.C. J. Chromatogr. (1979) [Pubmed]
  31. Striatal synaptosomal dopamine synthesis: evidence against direct regulation by an autoreceptor mechanism. Compton, D.R., Johnson, K.M. Eur. J. Pharmacol. (1985) [Pubmed]
  32. Research and clinical potential of receptor based radiopharmaceuticals. Kilbourn, M.R., Zalutsky, M.R. J. Nucl. Med. (1985) [Pubmed]
  33. Modification of sexual behavior of Long-Evans male rats by drugs acting on the 5-HT1A receptor. Rehman, J., Kaynan, A., Christ, G., Valcic, M., Maayani, S., Melman, A. Brain Res. (1999) [Pubmed]
  34. A comparison of the effects of neuroleptics on phencyclidine-induced behaviors in the rat. Sturgeon, R.D., Fessler, R.G., London, S.F., Meltzer, H.Y. Eur. J. Pharmacol. (1981) [Pubmed]
  35. Droperidol inhibits tracheal contraction induced by serotonin, histamine or carbachol in guinea pigs. Sato, T., Hirota, K., Matsuki, A., Zsigmond, E.K., Rabito, S.F. Canadian journal of anaesthesia = Journal canadien d'anesthésie. (1996) [Pubmed]
  36. Benperidol for schizophrenia. Leucht, S., Hartung, B. Cochrane database of systematic reviews (Online) (2005) [Pubmed]
  37. Comparison of three 18F-labeled butyrophenone neuroleptic drugs in the baboon using positron emission tomography. Arnett, C.D., Shiue, C.Y., Wolf, A.P., Fowler, J.S., Logan, J., Watanabe, M. J. Neurochem. (1985) [Pubmed]
  38. Sensitive analysis of butyrophenone neuroleptics by high-performance liquid chromatography with ultraviolet detection at 254 nm. Parkinson, D. J. Chromatogr. (1985) [Pubmed]
  39. Polymorphism of butyrophenones related to haloperidol. Azibi, M., Draguet-Brughmans, M., Bouche, R. Journal of pharmaceutical sciences. (1984) [Pubmed]
  40. Risperidone appears safe in patients with antipsychotic-induced blood dyscrasias. Mahmood, T., Silverstone, T., Spittle, B. International clinical psychopharmacology. (1996) [Pubmed]
 
WikiGenes - Universities